Create a 22-slide interactive CLM presentation for fictional Avenlith Biopharma and its fictional CENDORYA therapy. Title: A life in motion. This is a creative training example, not medical information. AUDIENCE AND JOB Support a concise professional discussion that can move from the person to circulation, then to evidence and its limits. Make the short route useful on its own, with optional deeper exploration. Write clear finished draft copy rather than filling slides with instructions. Use no real pharmaceutical company, product or patient names. CREATIVE DIRECTION Use a sophisticated editorial system: pearl backgrounds, charcoal type, crimson accents, generous negative space, large readable headlines and a consistent navigation bar. Keep the opening cinematic, the science visual and the evidence precise. Use a 16:9 canvas. Compose each slide around one primary question. Do not apply one repetitive card layout to every page. IMAGERY AND MEDIA Propose an architectural opening still or short muted film with an intentional poster. Ask for a refined three-dimensional circulation or artery illustration. Include a labeled static equivalent and a concise anatomical explanation. Give video a deliberate playback policy on leaving and returning. Keep narration optional and provide a transcript. Music should support the opening and remain low beneath speech. Use purposeful motion to reveal hierarchy; provide an understandable reduced-motion state. STORY AND INTERACTION Create the following 22 slides. Use the section descriptions as the creative brief, not as text to copy verbatim onto the slides. Preserve their evidence and qualifications. Use visible, readable route choices. Keep the outcome on returning from a deeper view predictable. 1. A life in motion Open with the person behind the blood-pressure reading. Introduce CENDORYA, a fictional Avenlith Biopharma therapy, with a calm architectural image, a restrained crimson accent and a choice to explore the story or circulation. 2. Start with a question Offer three discussion questions: how the circulation works, what the synthetic study measured, and what remains uncertain. Invite a deliberate choice of up to two questions; never infer that visiting a slide answers a question. 3. The person behind the reading Use a fictional adult persona and one concise everyday observation. Avoid medical advice or an implied treatment recommendation. Give the discussion room to move toward science or evidence. 4. Read the pressure Explain systolic and diastolic measurements using clearly labeled schematic information. Keep units visible. Explain that the invented trial endpoint measures a group mean change. 5. The circulation atlas Plan an illustrative circulation scene with distinct heart, artery and vessel-wall views. Pair each visual with a readable text explanation. Supply a static view for readers who cannot use the interactive scene. 6. Inside the artery Reveal the vessel wall in two or three labeled stages. Keep explanatory copy beside the anatomical region. Treat the anatomy as a simplified educational illustration. 7. Science Bridge Separate schematic physiology, the invented treatment mechanism, and the synthetic measured endpoint into distinct steps. Do not imply the trial proves every causal connection. 8. A closer perspective Use a generous illustration and a short discussion question to connect the story to the evidence. Keep the clinical conclusion open until the study design and limitations have been shown. 9. The product concept Introduce the fictional CENDORYA 5 mg concept. State that no real prescribing information exists. Do not present use, dose or suitability as clinical guidance. 10. Inside AXIS-1 Show the invented randomized, double-blind, placebo-controlled, parallel-group, eight-week study. Randomized: 300 per arm. Full analysis: 292 per arm. Safety: 300 per arm. Keep these populations separate. 11. Evidence Lens / pressure Week eight mean seated systolic pressure change: CENDORYA −14.2 mmHg; placebo −7.1 mmHg. Difference −7.1 mmHg, synthetic 95% interval −9.2 to −5.0. Plan chart, exact values, difference/interval and source views from the same dataset. The result does not establish cardiovascular outcomes, individual response or durability beyond eight weeks. 12. Evidence Lens / response Exploratory threshold endpoint: at least 10 mmHg reduction at week eight. CENDORYA: 164/292 (56.2%). Placebo: 120/292 (41.1%). Plan percentage, exact count and aggregate proportion views. Do not imply a supplied multiplicity-adjusted inference or a clinical treatment target. 13. Trial Boundary Explorer Separate eligibility, baseline representation, subgroup evidence and unknown information. Provide finite fictional discussion scenarios. Do not calculate suitability or make a recommendation. 14. Challenge Mode Offer fixed discussion questions about comparator, measurement, uncertainty, population and follow-up. Each choice should reveal the relevant existing evidence and its limit. Keep the trial result fixed. 15. Time Window Show only observation times supplied in the fictional dossier. Keep efficacy, safety, discontinuation and follow-up in separate lanes. Leave unavailable observations empty; do not interpolate or invent week-twelve results. 16. Safety in view Synthetic safety population: 300 per arm. Any treatment-emergent adverse event: 64 vs 49. Dizziness: 18 vs 10. Headache: 13 vs 12. Low blood pressure: 9 vs 3. Serious events: 2 vs 2. State that all counts are invented demonstration values. 17. Who completed the study? Show all-cause discontinuation: 18/300 vs 15/300. Keep randomized, full-analysis and safety denominators visible. Do not silently substitute the 292-per-arm efficacy population. 18. The measurement matters Revisit the continuous versus threshold endpoints and the eight-week window. Explain what the synthetic values establish within the example and what they cannot answer. 19. Question Trail / review Return to the selected questions. Let the reader deliberately mark each discussed or unresolved. Do not count a page visit as an answer, or imply persistent CRM tracking. 20. Evidence Receipt Plan a local text recap of the evidence views inspected, selected questions, discussed/unresolved state, qualifications and source. Make downloading explicit. Do not imply email delivery or persistent clinical records. 21. Context & sources Identify Avenlith synthetic study dossier, AXIS-1 v1.0, tables 1–5, as invented for demonstration. Include clear limits, an anatomy explanation and the fictional-content notice. 22. The next conversation Close on one clear discussion action. Keep a return to the atlas and source context available. Retain the fictional-content notice and avoid a clinical call to action. EVIDENCE RULES All numbers are synthetic and must stay labeled as invented demonstration data. Reuse the same values across charts, tables, tooltips and narrative. Keep endpoint, unit, comparator, population, denominator and time window together. Do not invent a result, interpolate a missing observation, infer individual outcomes from group means, or turn exploratory numbers into a treatment recommendation. Preserve uncertainty and source context in every evidence view. DRAFT DELIVERY AND REVIEW Create a coherent editable first draft. Keep editable text separate from images where supported. Name reusable groups and components clearly. Build source, menu and back controls consistently. Keep all media and interactions understandable without animation or audio. Where a requested interaction needs further authoring, make the follow-up explicit in the draft instead of presenting a decorative control as working. Keep the fictional-content notice visible. Return a concise slide outline, a list of generated or required assets, the draft interaction structure and a review checklist. I will inspect the generated proposal and preview before accepting it.